Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.

@article{Du2018LiposomalNC,
  title={Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.},
  author={Yang Du and Xiaolong Liang and Yuan Li and Ting Sun and Huadan Xue and Zhengyu Jin and Jie Tian},
  journal={Cancer letters},
  year={2018},
  volume={414},
  pages={
          230-238
        }
}
Programmed death ligand-1 (PD-L1) is a central element in cancer therapies targeting immune checkpoints, and its expression is an important predictor of the therapeutic response. With recent approvals of therapeutic antibodies against PD-L1 and PD-1, noninvasive detection methods are now urgently needed to quantify PD-L1 expression in tumors and to evaluate the response to immune therapies. However, only few such methods are available. Thus, we fabricated nanohybrid liposomal cerasome… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
1 Citations
32 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 32 references

S

  • N. A. Rizvi, M. D. Hellmann, J. R. Brahmer, R. A. Juergens, H. Borghaei
  • Gettinger, L.Q. Chow, D.E. Gerber, S.A. Laurie, J…
  • 2016

V

  • C. Pfirschke, C. Engblom, S. Rickelt
  • Corte z-Retamozo, C. Garris, F. Pucci, T…
  • 2016

rdoll, Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer

  • S. L. Topalian, J. M. Taube, R. A. Anders, D. M. Pa
  • therapy, Nat R ev Cancer,
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…